Encap Drug Delivery

A division of

All News

Press releases, news and updates.

Lonza Completes Acquisition of Capsugel

Lonza announced today that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. (“Capsugel”) from KKR...

Lonza to Acquire Capsugel

Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and Consumer Healthcare Industries

Capsugel Expands Capabilities for Early-Phase Development through Commercial Manufacturing across

Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it is expanding the technology platforms and capabilities at its product development and manufacturing sites in Edinburgh, Scotland, and Ploërmel and Strasbourg, France.

Life Sciences in Scotland feature

Business Quarter (a leading business publication in Scotland) has published an article on the Life Sciences industry in Scotland. The article features Encap Drug Delivery and quotes from Stephen Brown. The article highlights the advantages of delivering a drug as a liquid in capsule versus as a solid tablet or powder in a capsule, Capsugel’s acquisition of Encap, Encap’s growth, and the industry’s attraction to Scotland.

Encap Drug Delivery supports MGB Biopharma oral product development programme

Encap Drug Delivery have been supporting MGB Biopharma with their MGB-BP-3 drug development programme since 2012 and are pleased to provide a link to the company’s latest press release - MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD) for MGB-BP-3.

The News Capsule Issue 11

Capsugel exhibits at PBP conference

Capsugel exhibits at the 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology in Glasgow

The News Capsule Issue 10

The 10th issue of The News Capsule is now available to download.

Capsugel announces major expansion at Livingston site

The first phase of the expansion includes new analytical, formulation and quality laboratories designed to address customers' bioavailability, high-potency API and other formulation challenges. The second phase, which is scheduled to begin later this year, will significantly expand commercial manufacturing capacity for the site's existing technologies and bring other formulation and development technologies, including spray dried dispersion, to this location

Formulation development of novel abuse deterrents article

The Controlled Release Society (CRS) was founded in the USA in 1978 to advance the science and technology of controlling the release and delivery of active agents. It is recognised worldwide as the premier professional society in this still developing field. The CRS is establishing local "chapters" of the organisation around the World and the United Kingdom Controlled Release Society was formed in 1994. In 1998, Ireland joined forces and the United Kingdom and Ireland Controlled Release Society (UKICRS) was formed. The UKICRS addresses a broad range of research fields based on controlled release which include agriculture, veterinary, food and cosmetic sciences.

Capsugel completes $25m SDD expansion at Bend site

To read the full article please click on the following link: http://www.in-pharmatechnologist.com/Drug-Delivery/Capsugel-completes-25m-SDD-expansion-at-Bend-site.

Healthy Directions Has Chosen Licaps® for its Krill Oil Product

Licaps® liquid-filled hard capsule technology has been chosen by Healthy Directions to encapsulate its Krill Omega Defense™

Capsugel Combines Lipid Bioavailability and Modified Release in One Technology

As a follow-up to the company's October 7 announcement regarding commercial availability of our lipid multi-particulate (LMP) technology, Nutritional Outlook recently interviewed Capsugel's Peter Zambetti about the technology’s application in the Health & Nutrition space.

Capsugel Advances the First Intrinsically Enteric Capsule Technology

Expands lead-user program for breakthrough technology, providing customers with a new approach for enteric drug delivery

Capsugel in the News:

At the 2014 Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS) earlier this week, Capsugel's Paul Davis and John Davidson hosted a presentation titled: "Top 10 Tips for Formulators and Manufacturing to Optimize Encapsulation." The presentation focused on how the path to successful encapsulation starts in the lab, not on the factory floor.

Capsugel Awarded EXCiPACT Certifications for Excipient Good Manufacturing Practices

Morristown, N.J., October 1, 2014 - Capsugel announced today that it has received EXCiPACT certification for its sites in Bornem, Belgium, and Colmar, France.

Encap Drug Delivery Celebrate 25th Birthday

Since the founding of the company in 1989, by Bill and his partners, the company has grown and developed into a world class organisation providing drug delivery and development services to clients across the globe.

Capsugel enters agreement with Chiasma

Morristown, N.J. April 28, 2014 - Capsugel today announced an agreement with Chiasma, Inc., wherein Capsugel Dosage Form Solutions (DFS) business unit is scaling up manufacturing for the only investigational oral form of octreotide in clinical development.

Capsugel's Encap Drug Delivery announces collaboration with Lipocine Inc.

Encap Drug Delivery, part of Capsugel’s Dosage Form Solutions (DFS) business unit and the leader in liquid-fill hard capsule development and manufacturing, today announced a collaboration with Lipocine Inc. to manufacture Phase 3 clinical trial and ICH stability registration batches of Lipocine’s oral testosterone product, LPCN 1021

The News Capsule Issue 9

We are proud to share with you the latest issue of the DFS newsletter: The News Capsule.

Capsugel Completes Acquisition of Bend Research

Capsugel announces that it has completed its acquisition of Bend Research Inc., a recognized industry leader in bioavailability enhancement. Bend Research is now part of Capsugel's Dosage Form Solutions (DFS) business. DFS integrates Capsugel’s proprietary technology platforms, formulation R&D centers and finished dosage manufacturing sites to deliver innovative solutions to customers.

Capsugel Expands Global Manufacturing for Finished Dosage Forms

Capsugel's Dosage Form Solutions (DFS) business unit unveiled extensive upgrades and expansions to three of its manufacturing facilities in the United States and Europe, deepening the company's finished dosage form capabilities as part of its Lipidex® technology platform.

The News Capsule issue 8

The 8th issue of The News Capsule is now available for download.

Capsugel Launches LIPIDEX® Technology Platform

Capsugel announces the launch of its new LIPIDEX® technology platform, which integrates the company’s lipid, liquid and semi-solid fill technologies, extensive product development experience, and commercial manufacturing infrastructure. The LIPIDEX platform will enable Capsugel’s Dosage Form Solutions (DFS) business unit to accelerate and improve the development of innovative products for its pharmaceutical and nutraceutical customers.

Capsugel acquires Encap Drug Delivery

Capsugel today announced that it has acquired Encap Drug Delivery.

Encap Drug Delivery establishes Hot Melt Extrusion (HME) capability

Encap Drug Delivery (EDD) and the School of Pharmacy, Queen’s University Belfast have received funding from the Technology Strategy Board and the Scottish Government that will allow both to enter into a collaborative Knowledge Transfer Partnership (KTP) on Hot Melt Extrusion (HME).

The News Capsule, issue 7

The 7th issue of The News Capsule, Encaps very own newsletter is now available for download. The newsletter has been designed to share some of the companys recent highlights and developments with you.

Encap Announces $2M Capital Expenditure Programme

Encap Drug Delivery announces a $2 million capital expenditure programme to support its growing CMO activities. Following the earlier expansion in 2008 when the company completed a $3 million investment involving an expansion of the Oakbank Park Way facility to provide two additional clean room suites including a High Potency facility and further expansion of its development laboratories, Encap is now providing new investment for additional high volume manufacturing equipment

D3 Pharma and Encap Drug Delivery continue partnership

D3 Pharma Limited today announces its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, PlenacholTM, for the treatment of vitamin D deficiency and insufficiency.

The News Capsule, Issue 6

The 5th issue of The News Capsule – Encap’s very own newsletter is now available for download. The newsletter has been designed to share some of the company’s recent highlights and developments with you.

New commercial product for Encap Drug Delivery

Encap Drug Delivery adds New Commercial Product to Portfolio

Encap Drug Delivery shortlisted for Life Sciences Award

Encap Drug Delivery has been shortlisted in the Life Sciences Business Leadership 2011 Category, for the Scottish Enterprise Life Sciences Awards 2012.

The News Capsule, issue 5

The 5th issue of The News Capsule – Encap’s very own newsletter is now available for download. The newsletter has been designed to share some of the company’s recent highlights and developments with you.

Encap Drug Delivery and Lena Nanoceutics to Develop Nano-Capsule Technology

Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena's proprietary nano-particle engineering technology with Encap's liquid filled hard capsule technology.

Encap Drug Delivery introduces Colon-Screen

Encap Drug Delivery introduces Colon-Screen to evaluate the potential to formulate drug compounds for oral delivery to the colon

The News Capsule, issue 4

The 4th issue of The News Capsule - Encap's very own newsletter is now available for download. The newsletter has been designed to share some of the company’s recent highlights and developments with you.

Encap Drug Delivery Oral Drug Delivery Meeting 2011

On March 4th 2011, Encap Drug Delivery were delighted to host their second Oral Drug Delivery Meeting. This followed on from the success of the first Oral Drug Delivery Meeting last year.

Full4Health Collaboration

Encap involved in international food and obesity study

Encap Drug Delivery FDA Inspection

Encap facility classified as acceptable after recent US FDA inspection

Encap Drug Delivery announces collaboration agreements with Probac AB and D3 Pharma for the development and manufacture of Specials product

Encap announces two new collaboration agreements

Encap Drug Delivery receives patent approval for DuoCap capsule system

Encap Drug Delivery receives patent approval for DuoCap capsule system

Jane Fraser joins as R&D Director

Encap, the global drug delivery solutions provider, today announced the appointment of Jane Fraser as Research and Development Director

Encap hosts Oral Drug Delivery seminar in Edinburgh

Leading academic and industrial experts within oral drug delivery present series of talks to attendees

Encap announces working partnership with Alfa Chemicals

Alfa to promote Encap services alongside Gattefosse's range of lipid excipients

Encap Drug Delivery announces colonic drug delivery licensing deal

Encap Drug Delivery and The School of Pharmacy agree colonic drug delivery licensing deal

Encap Newsletter is Launched

The last 12 months have been a very busy and exciting time for Encap Drug Delivery, including doubling our facility size and gaining FDA approval. The News Capsule has been designed to share some of the company's recent highlights and developments with you.

Encap and Probac AB announce exclusive collaboration agreement

Encap Drug Delivery and Probac AB announce a collaboration agreement for the development of an oral probiotic for the treatment of antibiotic associated diarrhoea.

MHRA audit success

Encap Drug Delivery announces recent successful MHRA audit results.

Encap Drug Delivery celebrates 20 year anniversary

2009 marks Encap Drug Delivery's 20th anniversary.

ABUSOLVE Used for Abuse Resistant Opioid

Encap's novel ABUSOLVE technology successfully used to develop new abuse resistant medication.

Increased US focus for Encap

Encap Drug Delivery has received official notification from the US Food and Drug Administration (FDA) that its facility is now classified as acceptable based on the facility inspection which took place earlier this year.

2008 Innovation Award Winners

2008 West Lothian Chamber of Commerce Business Excellence Innovation Award.

Encap's £3 million high potency manufacturing expansion is officially opened

Encap are delighted to announce that Nicola Sturgeon, Deputy First Minister and Cabinet Secretary for Health and Wellbeing, has officially opened the second and final phase of our new £3 million expansion, on 23rd September 2008.

Robbie Stewart joins as Sales Director

Encap, the international drug delivery solutions provider, announced today the appointment of Robbie Stewart as Sales Director.

Encap Drug Delivery Strengthens Capability in High-Potency and Cytotoxic Encapsulation

Encap, the international drug delivery solutions provider, today announced that it has signed an agreement with Thermal Transfer Limited (TTL) to build a £3 million state-of-the-art pharmaceutical development and manufacturing facility in Livingston, Scotland.

Dr. Stephen Brown joins as R&D Director

Encap, the international drug delivery solutions provider, has strengthened its Board of Directors and appointed Dr Stephen Brown as R&D Director with immediate effect.

Encap Drug Delivery Announces Plans for Expansion

Encap, the international drug delivery solutions provider, announced today that it has signed a Head of Terms with Kenmore Capital Oakbank Ltd.